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Introduction
Adenoviruses possess many obvious advantages as
gene-therapy vectors, particularly with regard to the
ease of generating high-titre recombinant virus and the
wide range of cell types that are susceptible to efficient
transduction by such viruses [1]. Because susceptible
cell types include nondividing cells, adenoviruses are
well suited to gene delivery in vivo, which is otherwise
difficult to achieve. Moreover, adenoviral vectors can
accept large amounts of additional DNA, 30 kb or more
in the case of the latest gutted vectors (see below).
Such advantages have led to their widespread applica-
tion both in preclinical and clinical studies. So far, 86
clinical trials, over 20% of all human gene-therapy pro-
tocols, have made use of adenoviruses for gene deliv-
ery. Until recently, adenoviruses had also been consid-
ered safe, a reputation now tarnished by the death in
1999 of a patient who had received a large dose of
recombinant adenovirus.
Adenovirus has been used in a number of preclinical
studies pertaining to the gene therapy of both rheumatoid
arthritis and osteoarthritis. By the use of this vector, genes
have been successfully delivered to intra-articular tissues,
including the synovium [2–4], cartilage [5,6–9], menisci
[10,11], and ligaments [12]. Systemic delivery has been
achieved by intramuscular and intravenous injection. More-
over, there are several reports of the successful genetic
treatment of animal models of arthritis using adenovirus as
the delivery system [4,13–19].
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Abstract
Recombinant adenoviruses are straightforward to produce at high titres, have a promiscuous host-
range, and, because of their ability to infect nondividing cells, lend themselves to in vivo gene delivery.
Such advantages have led to their widespread and successful use in preclinical studies of arthritis
gene therapy. While adenoviral vectors are well suited to ‘proof of principle’ experiments in laboratory
animals, there are several barriers to their use in human studies at this time. Transient transgene
expression limits their application to strategies, such as synovial ablation, which do not require
extended periods of gene expression. Moreover, there are strong immunological barriers to repeat
dosing. In addition, safety concerns predicate local, rather than systemic, delivery of the virus.
Continued engineering of the adenoviral genome is producing vectors with improved properties, which
may eventually overcome these issues. Promising avenues include the development of ‘gutted’ vectors
encoding no endogenous viral genes and of adenovirus–AAV chimeras. Whether these will offer
advantages over existing vectors, which may already provide safe, long-term gene expression following
in vivo delivery, remains to be seen.
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Success in preclinical studies raises the obvious question
of clinical applicability, discussion of which forms the
basis of this commentary.
Adenoviral vectors
Wild-type adenovirus contains a single, 36-kb, double-
stranded DNA genome flanked by inverted terminal
repeats. There are over 50 serotypes, from which
serotypes 2 and 5 have been most developed for use as
gene-therapy vectors. This virus infects the upper respira-
tory tract, producing symptoms similar to those associated
with colds and influenza, but as far as is known, it does not
normally cause more serious disorders.
After infection, the viral DNA escapes from the lysosome
and is transported to the nucleus of the cell, where it per-
sists as an episome; multiple genomes can coexist within
the nucleus of an infected cell. The adenoviral genome has
eight transcriptional units, expressed in temporal
sequence as early (E), intermediate (I), and late (L) genes.
There are four early genes (E1–E4), encoding proteins
necessary for the replication of the viral genome. E1A is
the first viral gene expressed, and its product trans-
activates the other promoters of early genes [20].
The first-generation vectors were constructed by deleting
the E1 and E3 regions of the adenoviral genome. This
strategy was intended to prevent expression of the late
genes, upon which viral replication depends, and provide
loci into which transgenes could be cloned, usually under
the transcriptional control of a heterologous promoter.
Recombinant adenoviruses of this type proved to be very
useful vectors, infecting a wide variety of cell types very
efficiently with minimal toxicity. The utility of these vectors,
however, is limited continued synthesis of viral proteins by
infected cells, despite the genetic deletions. These pro-
teins render infected cells antigenic and thus liable to
elimination by the immune system, a problem exacerbated
by the subsequent discovery that the E3 domain of the
virus encodes immunosuppressive proteins.
Second-generation vectors have deletions in the E2 or E4
regions of the genome [21]. These second-generation
vectors are clearly improved with respect to immunogenicity
and toxicity. It is unclear, however, whether these vectors’
performance regarding gene expression is improved, as the
inactivation of proteins encoded by E4 has been shown to
impair seriously expression from heterologous promoters
[22]. In the latest versions of adenoviral vectors, all viral
coding sequences have been eliminated [23]. Production of
these so-called ‘gutted’ vectors can be problematic and
their ability to express transgenes in various tissues remains
under investigation. Further improvements include the con-
struction of adenovirus/adeno-associated virus chimeras
that have the potential to provide both high transduction
efficiencies and long-term transgene expression.
There are two reasons why it has proved difficult to obtain
long-term gene expression with adenovirus. The first
reflects the persistence of viral gene expression in cells
infected with first-generation vectors. This renders the
transduced cells immunogenic and thus liable to elimina-
tion by cytotoxic T lymphocytes [24]. Moreover, it appears
that adenoviruses infect antigen-presenting cells, includ-
ing dendritic cells, very effectively after delivery in vivo
[25], contributing to the anti-adenoviral immune response.
Of interest is our observation that transgene expression
can persist for over a year in cells of the intervertebral
discs of immunocompetent rabbits when first-generation
adenovirus is used [26]. This finding suggests that long-
term gene expression is possible in cells that are non-
dividing and protected from immune surveillance.
The episomal nature of genes delivered by adenoviruses is
a second factor limiting the duration of gene expression.
Episomal DNA is rapidly lost from dividing cells, but may
be retained by nonmitotic cells. There are reports that
genes delivered by gutted viruses are expressed for
extended periods of time in organs such as liver and
muscle, where cell division is rare.
Regardless of whether or not viral genes are expressed in
transduced cells, all recombinant adenoviruses, like their
wild-type parent strains, are highly antigenic. Most of us
already carry antibodies to type 5 adenovirus. Further-
more, there is substantial experimental evidence that a
single administration of a therapeutically useful dose of
adenovirus generates a sufficient immune response to
prevent successful readministration of the same vector
[27]. Strategies to overcome this include switching of
serotype, transient immunosuppression, ‘tolerisation’ (the
induction of tolerance), and attaching polyethylene glycol
(PEG) moities to the virus (‘PEGylation’). Gene delivery ex
vivo using a later-generation virus would also overcome
problems associated with the immunogenicity of the aden-
ovirus, but this would deprive the vector of one of its major
advantages, efficient gene transfer in vivo.
The antigenicity of adenoviruses not only interferes with
gene delivery, but also causes pathology, usually inflamma-
tion. This has been seen after the intra-articular injection of
adenovirus in mice [28], rats [15], and rabbits [3], although
not all authors have noted it [2]. Some of the variation may
be due to batch differences. Depending upon the prepara-
tion, only 1–10% of recombinant virions may be infectious.
Although noninfectious, the other 90–99% of the viral par-
ticles are antigenic and can contribute to inflammation. The
purity of the viral suspension also affects its properties, and
incomplete removal of cellular debris or chemicals used in
the preparation of the virus will affect performance. In addi-
tion, adenovirus may be intrinsically inflammatory as a result
of its ability to activate MAP kinases and NFkB by binding
to integrins on the cell surface [29,30].Arthritis Research    Vol 3 No 3 Evans et al
Before evaluating the future utility of adenoviral vectors in
the gene therapy of arthritis, it is worth reviewing briefly
the anti-arthritic strategies to which these vectors might
be applied.
Strategies for the gene therapy of arthritis
Three major issues influence the present analysis [31]:
• Will the gene therapy be local or systemic?
• Will prolonged gene expression be necessary?
• Will redosing be necessary?
As its name suggests, local gene therapy implies that the
gene will be delivered to a discrete anatomical location.
For arthritis gene therapy, this is normally the joint, particu-
larly the synovial lining of the joint [32], although it could
also involve the use of cells with the ability to home in on
joints [33]. The aim is to expose diseased tissues to the
gene treatment without involving nontarget organs. Sys-
temic delivery, in contrast, implies that the effects of the
gene treatment are disseminated; this is achieved by, for
instance, delivering genes encoding secreted, circulating
products to tissues such as muscle, liver, and skin. The
advantages of local, intra-articular gene delivery include a
stronger therapeutic effect on the tissues of the joints with
lower undesirable side effects. Systemic therapy, however,
should provide greater benefit towards extra-articular man-
ifestations of disease and provide a more expeditious
route for treating polyarticular arthritis [31].
Strategies for the gene therapy of rheumatoid arthritis can
be loosely divided into those that require prolonged
periods of gene expression and those that do not. Among
those not requiring long-term gene expression are local
therapies intended to ablate the rheumatoid synovium by
the delivery of, for example, apoptosis genes or the herpes
thymidine kinase gene in conjunction with ganciclovir
[34,35]; this drug is at present the subject of a human
clinical trial. Success in such ‘hit-and-run’ protocols may
require the transgene to be expressed for as little as one
or two days, a duration that is easily achieved by existing
adenoviral vectors. Experience with more conventional
methods of synovial ablation suggests that remissions as
long as several years may be obtained by this route. Sub-
sequent recurrence of symptoms may be dealt with by
repeating the gene therapy.
It may also prove possible to achieve prolonged tolerance
or anergy in rheumatoid arthritis if immunocompetent cells
are exposed for short periods of time to the products of
the appropriate genes. Candidates include molecules that
interfere with the costimulation of T lymphocytes and
certain immunomodulatory cytokines [36]. Exactly how
short a time these genes would need to be expressed for
is impossible to predict for lack of experimental data, but
timescales of a week or two, which are readily achievable
with adenovirus vectors, are not unreasonable. The ability
of the viruses to infect antigen-presenting cells in vivo [25]
makes them suitable for applications to induce tolerance
through expression of immunosuppressive gene products.
Redosing will also be necessary if such therapies have a
temporary effect. However, so little is known about the
induction of tolerance by gene transfer that it is impossible
to predict the frequency with which a successful tolerising
gene treatment might need to be readministered.
In contrast to the above, most strategies for the treatment
of both rheumatoid arthritis and osteoarthritis require
extended periods of gene expression – possibly for the
patient’s lifetime. Such strategies include the expression
of IL-1 and TNF antagonists, as well as type 2 cytokines,
cartilage growth factors, and so forth [31,37]. The expres-
sion of genes encoding such proteins may also need to be
regulated, but, as this problem is not unique to adenoviral
delivery, we do not discuss it further here except to note
that these vectors probably provide sufficient space for
the necessary regulatory elements.
Suitability of adenoviruses in arthritis gene
therapy
It is questionable whether adenoviruses are suited to
arthritis gene therapies requiring long-term gene expres-
sion, regardless of whether these are systemic or local.
The use of later-generation recombinant adenoviruses
obviates the immunological problems engendered by the
residual expression of viral proteins but not the more fun-
damental problem of episomal gene delivery. Continued
engineering of the virus may improve the persistence of
gene expression, but most investigators seeking pro-
longed gene expression are turning to alternative existing
vectors, such as adeno-associated viruses (‘AAVs’)
[38–40]. A related question for therapies directed
towards synovium is the turnover kinetics of synoviocytes
in health and disease. Clearly, prolonged transgene
expression cannot be achieved by transducing cells that
die, regardless of the vector system employed.
Problems associated with transient gene expression can
be obviated by repeat dosing, but frequent redosing is not
always practical and is impaired by the strong antigenicity
of adenoviruses. Of the various strategies mentioned
above for dealing with this issue, immunosuppression may
be acceptable in RA, where immunosuppressive agents
are already used therapeutically. The use of PEGylated
virus and vectors developed from different serotypes is
also of interest.
Safety concerns promise to curtail the application of adeno-
viral vectors to the systemic gene therapy of nonlethal
diseases such as arthritis. The death of a patient with
mild ornithine transcarbamylase deficiency after infusion
of adenoviral vectors highlights this concern. Our own
experimental data are consistent with the notion thatAvailable online http://arthritis-research.com/content/3/3/142
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therapeutic doses of adenovirus run the risk of side
effects when delivered systemically. As noted by Whalen
et al [19], the amounts of adenovirus carrying the viral IL-
10 gene (ad-vIL-10) needed to treat collagen-induced
arthritis in mice by intravenous injection cause hepatitis.
Other investigators have not reported this, but we do not
know if they examined liver pathology. Significantly, ad-vIL-
10 delivered locally has a stronger anti-arthritic effect at a
much lower dose and without observable side effects [19].
There may, however, be a niche for adenovirus in the local
treatment of arthritis under conditions where neither long-
term gene expression nor frequent readministration is nec-
essary. The most immediate of such applications is synovial
ablation, as mentioned earlier. Indeed, we understand that
a human clinical study in which adenovirus will be used to
deliver the herpes thymidine kinase gene intra-articularly, in
conjunction with ganciclovir, has been given regulatory
approval in the Netherlands. If genetic synovectomy has a
similar clinical effect as synovectomy by other means, the
procedure may need to be repeated only rarely.
Conclusions
Adenoviral delivery systems are extremely useful in preclin-
ical studies, where their ease of manufacture and applica-
tion allows the rapid screening of candidate anti-arthritic
genes, testing of hypotheses, and evaluation of feasibility.
Nevertheless, at their present state of development, they
would appear to have limited clinical application to the
gene therapy of human arthritis. Their major problems
include limited duration of gene expression, difficulties in
repeat dosing, inflammatory responses, and questionable
safety. The use of present vectors seems restricted to
local, acute therapies such as those involving a genetic
synovectomy. Such restrictions may ease as continued
engineering of the virus produces vectors with improved
properties, but impatient investigators may wish to make
use of alternative existing vectors for which these prob-
lems already do not exist.
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